Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification

NCT07687004 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

DRUG: Sonrotoclax
DRUG: CM336 (BCMA/CD3 bispecific antibody)

Sponsor

Institute of Hematology & Blood Diseases Hospital, China